A Phase Ii Study Investigating Cabozantinib In Patients With Refractory Metastatic Colorectal Cancer (Agicc 17crc01)
JOURNAL OF CLINICAL ONCOLOGY(2020)
摘要
103Background: Therapeutic resistance to antiangiogenics in metastatic colorectal cancer (mCRC) inevitably develops via multiple mechanisms including upregulation of the MET kinase pathway. Cabozan...
更多查看译文
关键词
refractory metastatic colorectal cancer,cabozantinib,colorectal cancer
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要